[go: up one dir, main page]

TW200744575A - Methods of treating epileptogenesis - Google Patents

Methods of treating epileptogenesis

Info

Publication number
TW200744575A
TW200744575A TW095125162A TW95125162A TW200744575A TW 200744575 A TW200744575 A TW 200744575A TW 095125162 A TW095125162 A TW 095125162A TW 95125162 A TW95125162 A TW 95125162A TW 200744575 A TW200744575 A TW 200744575A
Authority
TW
Taiwan
Prior art keywords
group
phenyl
alkyl
methods
subject
Prior art date
Application number
TW095125162A
Other languages
English (en)
Inventor
Roy E Twyman
Bo-Yu Zhao
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37637731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200744575(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of TW200744575A publication Critical patent/TW200744575A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
TW095125162A 2005-07-12 2006-07-11 Methods of treating epileptogenesis TW200744575A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69862505P 2005-07-12 2005-07-12

Publications (1)

Publication Number Publication Date
TW200744575A true TW200744575A (en) 2007-12-16

Family

ID=37637731

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095125162A TW200744575A (en) 2005-07-12 2006-07-11 Methods of treating epileptogenesis

Country Status (16)

Country Link
US (1) US20070021501A1 (zh)
EP (1) EP1906946A2 (zh)
JP (1) JP2009501223A (zh)
KR (1) KR20080028485A (zh)
CN (1) CN101309680A (zh)
AR (1) AR054550A1 (zh)
AU (1) AU2006269462A1 (zh)
BR (1) BRPI0613010A2 (zh)
CA (1) CA2615127A1 (zh)
EA (1) EA200800295A1 (zh)
EC (1) ECSP088172A (zh)
IL (1) IL188728A0 (zh)
NO (1) NO20080739L (zh)
TW (1) TW200744575A (zh)
WO (1) WO2007008551A2 (zh)
ZA (1) ZA200801402B (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2446306T3 (es) * 2008-05-16 2014-03-07 Nono Inc. Uso de un inhibidor de psd-95 tratamiento para la epilepsia
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
CN109939092B (zh) 2013-03-12 2022-03-22 比皮艾思药物研发有限公司 用于预防或治疗小儿癫痫和癫痫相关综合征的苯基氨基甲酸酯化合物
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
HUE066912T2 (hu) * 2015-08-24 2024-09-28 Zogenix International Ltd Lennox-Gastaut szindróma kezelési eljárása fenfluramin alkalmazásával
CA3016253C (en) * 2016-02-29 2020-12-29 Bio-Pharm Solutions Co., Ltd. Sulfamate derivative compounds, processes for preparing them and their uses
US20190022166A1 (en) * 2017-07-18 2019-01-24 Creative Bio-Peptides Inc. Oral anti-inflammatory peptides to treat epilepsy, seizures and cns disorders
USRE50630E1 (en) 2017-10-31 2025-10-14 Creative BioPeptides, Inc. Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain
CN109920550A (zh) * 2018-12-25 2019-06-21 天津大学 一种基于dMRI研究青少年肌阵挛性癫痫的方法
US11510961B2 (en) 2019-12-19 2022-11-29 Creative Bio-Peptides, Inc. Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof
CN115501344A (zh) * 2022-09-29 2022-12-23 重庆医科大学 一种铁螯合剂的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
WO1997045160A1 (en) * 1996-05-31 1997-12-04 Southern Illinois University Methods of modulating aspects of brain neural plasticity by vagus nerve stimulation
ES2197078T3 (es) * 1999-02-09 2004-01-01 University Of Virginia Patent Foundation Compuestos derivados del felbamato.
ATE324108T1 (de) * 2001-02-27 2006-05-15 Ortho Mcneil Pharm Inc Carbamatverbindungen zur verwendung bei der prävention oder behandlung der bipolaren erkrankung
US7122576B2 (en) * 2001-02-27 2006-10-17 Plata-Salaman Carlos R Carbamate compounds for use in preventing or treating bipolar disorder

Also Published As

Publication number Publication date
US20070021501A1 (en) 2007-01-25
AU2006269462A1 (en) 2007-01-18
WO2007008551A2 (en) 2007-01-18
ZA200801402B (en) 2009-10-28
CA2615127A1 (en) 2007-01-18
ECSP088172A (es) 2008-03-26
BRPI0613010A2 (pt) 2010-12-14
EP1906946A2 (en) 2008-04-09
IL188728A0 (en) 2008-11-03
AR054550A1 (es) 2007-06-27
CN101309680A (zh) 2008-11-19
NO20080739L (no) 2008-04-10
EA200800295A1 (ru) 2008-12-30
WO2007008551A3 (en) 2008-06-19
JP2009501223A (ja) 2009-01-15
KR20080028485A (ko) 2008-03-31

Similar Documents

Publication Publication Date Title
NO20071921L (no) Fremgangsmater for behandling av epileptogenese og epilepsi
IL189003A0 (en) Methods for treating substance-related disorders
YU67703A (sh) Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja
MY138156A (en) Carbamate compounds for use in preventing or treating neurodegenerative disorders
WO2007008562A3 (en) Carbamate compounds for use in treating neurodegenerative disorders
TW200744575A (en) Methods of treating epileptogenesis
IL157590A0 (en) Carbamate compounds for use in preventing or treating bipolar disorder
MX2009004553A (es) Metodos para el tratamiento de trastornos cocleares y vestibulares.
IL157594A0 (en) Carbamate compounds for use in preventing or treating anxiety disorders
EA200700871A1 (ru) Способы нейропротекции
TW200701978A (en) Methods of treating epileptogenesis and epilepsy
IL159847A0 (en) Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
MY136733A (en) Carbamate compounds for use in preventing or treating psychotic disorders
MY149385A (en) Methods for treating substance-related disorders
CY1110672T1 (el) Χρηση των 2- φαινυλ-1,2-αιθανοδιολης- (δι) καρβαμικων για θεραπεια επιληπτογενεσης